Chicago’s regional broadcast, WGN-TV of the Tribune, America’s largest broadcasting group has shed light on ‘CARTISTEM^®’, MEDIPOST’s cartilage regenerating stem cell treatment.

On August 28 (local time), ‘Medical Watch’ a popular program of WGN-TV has reported that ‘CARTISTEM^®’ is currently available in the market after obtaining the permission of articles by the Food and Drug Administration in 2012 in Korea, and that 1 a clinical trials are being held at Harvard University’s Brigham and Women’s Hospital, Massachusetts, and Rush University Hospital, Chicago after receiving the FDA’s approval in America.

WGN-TV also introduced ‘CARTISTEM^®’ as “a stem cell treatment that helps our body to independently regenerate cartilage, and its effects have already been revealed through animal testing and clinical trials”.

Also, referring to the words of Professor Brian J. Cole, the head doctor of the CARTISTEM^®’s clinical trial, WGN-TV reported that “existing treatments including microfractures did not achieve satisfactory effects in cartilage regeneration, however with the use of ‘CARTISTEM^®’, long-term effect can be expected”.